Page last updated: 2024-09-05

lixivaptan and Acquired Nephrogenic Diabetes Insipidus

lixivaptan has been researched along with Acquired Nephrogenic Diabetes Insipidus in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Greenberg, A; Verbalis, JG1
Angers, S; Arthus, MF; Bernier, V; Bichet, DG; Bouvier, M; Laperrière, A; Lonergan, M; Morello, JP; Morin, D; Petäjä-Repo, U; Salahpour, A1

Reviews

1 review(s) available for lixivaptan and Acquired Nephrogenic Diabetes Insipidus

ArticleYear
Vasopressin receptor antagonists.
    Kidney international, 2006, Volume: 69, Issue:12

    Topics: Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Clinical Trials as Topic; Diabetes Insipidus, Nephrogenic; Fibrosis; Heart Failure; Humans; Hyponatremia; Osmolar Concentration; Polycystic Kidney Diseases; Pyrroles; Receptors, Vasopressin; Sodium; Tolvaptan; United States; United States Food and Drug Administration; Vasopressins

2006

Other Studies

1 other study(ies) available for lixivaptan and Acquired Nephrogenic Diabetes Insipidus

ArticleYear
Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants.
    The Journal of clinical investigation, 2000, Volume: 105, Issue:7

    Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Cell Line; Cell Membrane; COS Cells; Diabetes Insipidus, Nephrogenic; Flow Cytometry; Humans; Intracellular Fluid; Molecular Chaperones; Morpholines; Mutagenesis; Protein Folding; Pyrroles; Receptors, Vasopressin; Spiro Compounds

2000